Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug bintrafusp alfa gets Long-Term safety check in small Follow-Up trial

NCT ID NCT05061823

Completed Disease control Sponsor: EMD Serono Research & Development Institute, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 22 cancer patients who were already taking bintrafusp alfa in earlier trials, to see how safe it is over the long term and how long they live. Participants continued receiving the drug until it was no longer helping or became available commercially. The main goal was to track side effects, and researchers also looked at overall survival. It's a small, completed Phase 3 rollover study, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
bintrafusp alfa (M7824)
What this could lead to
If successful, this study could confirm that long-term use of bintrafusp alfa is safe and helps control cancer over time.
What could go wrong
This is a small rollover study with only 22 participants, so results may not apply broadly. Side effects are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer lung cancer lung neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER LUNG CANCER

Contacts and locations

Locations

  • Adana City Hospital - Parent Account

    Adana, Turkey (Türkiye)

  • Asan Medical Center

    Seoul, South Korea

  • BHI of Omsk region "Clinical Oncology Dispensary" - PARENT

    Omsk, Russia

  • Centre Hospitalier de l'Ardenne - PARENT

    Libramont, Belgium

  • Chang Gung Memorial Hospital,Linkou

    Taoyuan County, Taiwan

  • Communal Enterprise Volyn Regional Medical Center of Oncology of Volyn Regional Council - Department of Oncochemotherapy

    Lutsk, Ukraine

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica

    Lazio, Italy

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica

    Valencia, Spain

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

  • Hospital Universitario Ramon y Cajal - Servicio de Oncologia

    Madrid, Spain

  • NIH National Institutes of Health/GMB LTIB

    Bethesda, Maryland, 20892, United States

  • National Cancer Center Hospital

    Chūōku, Japan

  • National Cancer Center Hospital East

    Kashiwa-shi, Japan

  • Saitama Medical University International Medical Center

    Hidaka-shi, Japan

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Taichung Veterans General Hospital

    Taichung, Taiwan

  • The Center for Cancer and Blood Disorders a Division of American Oncology Partners of Maryland, P.A.

    Bethesda, Maryland, 20817, United States

  • Universitaetsklinikum Carl Gustav Carus TU Dresden - Medizinische Klinik I

    Dresden, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.